[go: up one dir, main page]

UY27993A1 - Derivados de 4-pirrolidino-fenil-bencil eter - Google Patents

Derivados de 4-pirrolidino-fenil-bencil eter

Info

Publication number
UY27993A1
UY27993A1 UY27993A UY27993A UY27993A1 UY 27993 A1 UY27993 A1 UY 27993A1 UY 27993 A UY27993 A UY 27993A UY 27993 A UY27993 A UY 27993A UY 27993 A1 UY27993 A1 UY 27993A1
Authority
UY
Uruguay
Prior art keywords
derivatives
pirrolidino
bencil
fenil
eter
Prior art date
Application number
UY27993A
Other languages
English (en)
Inventor
Synese Jolidon
Andrew William Thomas
Rene Wyler
Rosa Maria Rodriguez-Sarmiento
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27993A1 publication Critical patent/UY27993A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados 4-pirrolidino racémica o enantioméricamente puros, procesos para su preparación, composiciones farmacéuticas que comprenden dichos derivados, y su uso en la prevención y tratamiento de enfermedades, por ejemplo que están mediadas por inhibidores de monoamino oxidas B, en particular enfermedad de Alzheimer o demencia senil.
UY27993A 2002-09-20 2003-09-19 Derivados de 4-pirrolidino-fenil-bencil eter UY27993A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (1)

Publication Number Publication Date
UY27993A1 true UY27993A1 (es) 2004-03-31

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
UY27990A UY27990A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
UY27991A UY27991A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona domo inhibidores de maob
UY27993A UY27993A1 (es) 2002-09-20 2003-09-19 Derivados de 4-pirrolidino-fenil-bencil eter

Family Applications Before (2)

Application Number Title Priority Date Filing Date
UY27990A UY27990A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
UY27991A UY27991A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona domo inhibidores de maob

Country Status (31)

Country Link
US (4) US7235581B2 (es)
EP (3) EP1542971A1 (es)
JP (3) JP4335142B2 (es)
KR (3) KR100676015B1 (es)
CN (3) CN100400509C (es)
AR (3) AR041297A1 (es)
AT (2) ATE472530T1 (es)
AU (3) AU2003273901B2 (es)
BR (4) BR0314314A (es)
CA (3) CA2498785C (es)
CY (1) CY1110745T1 (es)
DE (2) DE60331559D1 (es)
DK (1) DK1542970T3 (es)
ES (2) ES2344557T3 (es)
GT (3) GT200300205A (es)
HR (3) HRP20050261A2 (es)
JO (2) JO2605B1 (es)
MX (3) MXPA05002880A (es)
MY (3) MY134480A (es)
NO (3) NO329754B1 (es)
NZ (3) NZ538048A (es)
PA (3) PA8583001A1 (es)
PE (3) PE20050077A1 (es)
PL (3) PL216030B1 (es)
PT (1) PT1542970E (es)
RU (3) RU2323209C2 (es)
SI (1) SI1542970T1 (es)
TW (3) TWI286132B (es)
UY (3) UY27990A1 (es)
WO (3) WO2004026825A1 (es)
ZA (3) ZA200501137B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
US7456210B2 (en) * 2004-08-02 2008-11-25 Hoffmann-La Roche Inc. Benzyloxy derivatives
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
BRPI0608466A2 (pt) * 2005-03-15 2010-01-05 Hoffmann La Roche método de preparação de derivados de éter 4-pirrolidinofenil benzìlico enantiomericamente puros
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
DE602006015215D1 (de) * 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
AU2014241759B2 (en) 2013-03-14 2017-10-19 Dart Neuroscience (Cayman) Ltd. Substituted naphthyridine and quinoline compounds as MAO inhibitors
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
RU2016118748A (ru) 2013-10-29 2017-12-05 Ф. Хоффманн-Ля Рош Аг Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
WO2016156124A1 (en) 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
WO2019065794A1 (ja) 2017-09-27 2019-04-04 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痛薬
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
EP3762364B1 (en) * 2018-03-08 2023-08-23 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
EP3932490B1 (en) 2019-02-27 2025-04-02 Kagoshima University Antipruritic agent using pac1 receptor antagonist
WO2021225161A1 (ja) 2020-05-08 2021-11-11 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) * 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
DE69025418T2 (de) 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
ATE253057T1 (de) * 1994-08-30 2003-11-15 Sankyo Co Isoxazole
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
WO1997033572A1 (en) 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
CA2398496C (en) * 2000-02-10 2009-05-19 Surgical Development Ag Urinary incontinence treatment with wireless energy supply
WO2001047441A2 (en) * 2000-02-14 2001-07-05 Potencia Medical Ag Penile prosthesis
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism

Also Published As

Publication number Publication date
HK1083499A1 (zh) 2006-07-07
RU2005111968A (ru) 2006-11-10
NO20050665L (no) 2005-04-18
JP4335140B2 (ja) 2009-09-30
TW200408624A (en) 2004-06-01
US7037935B2 (en) 2006-05-02
AU2003270213B8 (en) 2009-03-05
HK1084383A1 (en) 2006-07-28
AU2003270213B2 (en) 2009-02-12
HRP20050263A2 (en) 2006-12-31
JP2006503834A (ja) 2006-02-02
MXPA05002878A (es) 2005-05-27
WO2004026827A1 (en) 2004-04-01
BR0314631A (pt) 2005-08-02
AU2003270213A1 (en) 2004-04-08
WO2004026826A1 (en) 2004-04-01
CA2498785C (en) 2011-07-26
SI1542970T1 (sl) 2010-08-31
TWI331994B (en) 2010-10-21
AU2003273901B2 (en) 2008-07-10
RU2005111969A (ru) 2006-01-20
CN100503562C (zh) 2009-06-24
CA2496756C (en) 2012-01-10
ZA200501137B (en) 2006-12-27
AR041298A1 (es) 2005-05-11
CN100383118C (zh) 2008-04-23
MY135696A (en) 2008-06-30
DE60333202D1 (de) 2010-08-12
TW200413350A (en) 2004-08-01
JO2605B1 (en) 2011-11-01
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
US20040097578A1 (en) 2004-05-20
NZ538048A (en) 2007-05-31
EP1542969A1 (en) 2005-06-22
UY27990A1 (es) 2004-03-31
PA8583601A1 (es) 2004-09-16
BR0314299A (pt) 2005-12-13
KR20050057456A (ko) 2005-06-16
MY133332A (en) 2007-11-30
NO20050652L (no) 2005-03-08
MXPA05002880A (es) 2005-05-27
EP1542971A1 (en) 2005-06-22
AU2003273901A1 (en) 2004-04-08
ATE459601T1 (de) 2010-03-15
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
CN1681779A (zh) 2005-10-12
NZ538049A (en) 2007-05-31
PT1542970E (pt) 2010-07-19
RU2336267C2 (ru) 2008-10-20
PL376021A1 (en) 2005-12-12
CY1110745T1 (el) 2015-06-10
NO329754B1 (no) 2010-12-13
AU2003267381A1 (en) 2004-04-08
JP2006510596A (ja) 2006-03-30
NZ538046A (en) 2007-08-31
MY134480A (en) 2007-12-31
US20060122235A1 (en) 2006-06-08
CN100400509C (zh) 2008-07-09
KR20050057450A (ko) 2005-06-16
KR20050057466A (ko) 2005-06-16
US20040106650A1 (en) 2004-06-03
CA2496756A1 (en) 2004-04-01
HK1083498A1 (zh) 2006-07-07
JP2006503833A (ja) 2006-02-02
NO20050701L (no) 2005-03-02
US20040116707A1 (en) 2004-06-17
ES2344557T3 (es) 2010-08-31
DK1542970T3 (da) 2010-08-02
ES2338646T3 (es) 2010-05-11
ZA200501311B (en) 2006-10-25
HRP20050261A2 (en) 2006-05-31
RU2005111974A (ru) 2006-01-20
HRP20050262A2 (en) 2006-06-30
AU2003267381B2 (en) 2009-08-27
BR0314314A (pt) 2005-07-26
TWI286132B (en) 2007-09-01
TWI337604B (en) 2011-02-21
US7151111B2 (en) 2006-12-19
JO2604B1 (en) 2011-11-01
CA2498785A1 (en) 2004-04-01
BRPI0314631B1 (pt) 2018-04-17
DE60331559D1 (de) 2010-04-15
NO330012B1 (no) 2011-02-07
TW200410935A (en) 2004-07-01
CN1681777A (zh) 2005-10-12
CN1681778A (zh) 2005-10-12
US7235581B2 (en) 2007-06-26
CA2498335A1 (en) 2004-04-01
KR100681586B1 (ko) 2007-02-09
PE20050079A1 (es) 2005-03-01
AR041297A1 (es) 2005-05-11
PE20050078A1 (es) 2005-02-28
JP4335142B2 (ja) 2009-09-30
WO2004026825A1 (en) 2004-04-01
GT200300205A (es) 2004-04-29
KR100676015B1 (ko) 2007-01-30
ZA200501557B (en) 2005-09-08
JP4335141B2 (ja) 2009-09-30
UY27991A1 (es) 2004-03-31
PL376018A1 (en) 2005-12-12
PA8583001A1 (es) 2004-04-23
KR100676014B1 (ko) 2007-01-30
GT200300204A (es) 2004-04-29
EP1542970B1 (en) 2010-06-30
RU2336268C2 (ru) 2008-10-20
ATE472530T1 (de) 2010-07-15
PE20050077A1 (es) 2005-03-01
HRP20050263B1 (hr) 2013-09-30
RU2323209C2 (ru) 2008-04-27
PA8583501A1 (es) 2004-04-23
PL376019A1 (en) 2005-12-12
GT200300206A (es) 2004-04-29
AR041299A1 (es) 2005-05-11
US7122562B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
UY26930A1 (es) Amidas de ácido fenilciclohexanocarboxílico sustituido y su uso
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
FR2838969B1 (fr) Procede de sterilisation par haute pression de compositions pharmaceutiques sous forme micro ou nanodispersee et compositions ainsi obtenues
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
UY27931A1 (es) 2,3-dihidro-isoindol-1-onas
DOP2001000245A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150522